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Processing-Induced Disorder in Pharmaceutical Materials
Sheng Qi
15.1
Introduction
Disorder in pharmaceutical materials can be introduced through processing.Q1
A good example of unintentionally introduced disorder into the formulation is
the generation of a small number of defects at the surface of the tablets during
the compression of tableting process [1, 2]. The degree of the disorder can range
widely and may be as high as that found in amorphous materials, or it may be
relatively low such as is seen in localized defects. The defects can be in the form
of point defects, line defects, or plane defects [3]. These defects often can exhibit
diﬀerent levels of eﬀect in terms of altering the physical and mechanical proper-
ties of the ﬁnished product. If the amount of accumulated defects in the system
reaches a critical level, the material can be converted into an amorphous state,
and this conversion can impact on the clinical performance of the formulations.
The nature and quantity of the disorder are dependent on the intrinsic properties
of the material and the particular process used to manipulate the material. A
large amount of data has indicated that many of the diﬀerent processes used for
pharmaceuticals may cause disorder of the material. As an example, many recent
works have reported the diﬀerent physical stabilities of amorphous formulations
produced by diﬀerent methods [4–6]. This is likely associated with the diﬀerent
levels of disorder created by diﬀerent processing methods.
The amorphous state represents the highest level of disorder, which can be
recognized through the lack of organized long-range order. Often, during the pro-
duction of amorphous materials, other disordered states such as diﬀerent degrees
of defects (either diﬀerent quantity or diﬀerent type of defects) can be created.
The production of amorphous materials can be classiﬁed into thermodynamic-
and kinetic-based methods, as indicated in Figure 15.1 [3]. Thermodynamic
methods are those that follow the equilibrium phase transformation from liquid
to the solid state. In these methods, the processed materials are transformed to
their liquid state via either melting or dissolving in a solvent.The thermodynamic
methods include melt-based methods such as melt-quenching, melt-granulation,
hot-melt extrusion (HME), spray-congealing, dry powder coating, thermal
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Figure 15.1 Process-induced disorder. (Taken from [3].)
sintering/curing, and solvent-evaporation-based methods such as spray-drying,
freeze-drying and electrospinning. Kinetic-based methods rely on the gradual
disruption of the molecular arrangement of a crystalline material by progres-
sively creating defects. A typical kinetic-based method is milling. Once the
accumulation of the defects reaches a critical level, the material is likely to be
converted into an amorphous state. This chapter focuses on the major types of
pharmaceutical processing methods that have been widely reported to produce
disordered material either intentionally or unintentionally.
15.2
Pharmaceutical Processing
15.2.1
Milling
Milling is common and one of the most frequently used unit operations used by
the pharmaceutical industry for reducing the particle size of solids. When milling
is applied to crystalline solids, as a result of themechanical stresses inherent to the
milling process, disorder in the crystalline structure of the active pharmaceutical
ingredient (API) can be introduced either unintentionally or intentionally. These
disorders can take the form of defects in the crystal lattice, polymorphic transfor-
mations, complete loss of the crystalline lattice, and conversion to the amorphous
state [7–11]. These structural changes may be located only at the surface of the
solids, or they may penetrate through the bulk of the material. Depending on
the proportion of the material aﬀected, the presence of the disorder can often
lead to changes in the physical and chemical properties of the milled solids [11].
The conversion of a crystalline solid to its amorphous state via milling has been
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explained by three possible mechanisms: accumulation of crystal defects with a
higher free energy level than a certain critical level under kinetically favorable
conditions [7, 12]; local overheating during milling, which leads to melting and
rapid quenching of the API [7, 8, 11]; and obtaining the amorphous form of the
API from the intermediate state formed during polymorphic conversion of the
crystalline solid. For instance, the milling of form IV of fananserine could lead
to its intermediate amorphous state, which precedes the transformation of the
metastable form I polymorphs [11].
The possibility of intentionally generating an amorphous pharmaceutical prod-
uct through milling or cryo-milling (milling at extremely low temperature) has
been reported [7, 11–23].The amount of disorder induced by milling is governed
by many factors including the milling intensity, temperature, additives, and the
intrinsic properties of the solid such as glass transition temperature and crystal
structure [7, 11–23]. When milling at temperatures below the glass transition of
the amorphous API, the increase in Gibbs free energy drives the conversion of the
crystalline form to the amorphous form, as illustrated in Figure 15.2 [11]. In these
cases (milling at temperatures below the Tg of the API), the milling intensity
is crucial in determining the nature of the transformation [11]. Amorphous
conversion occurred when the 𝛾-form of crystalline indomethacin was milled
with high intensity at room temperature, which is below the Tg of amorphous
indomethacin, whereas only polymorphic transformation occurred when milled
with lower intensity below Tg [7]. In contrast, regardless of intensity, milling
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Figure 15.2 (a) Schematic TTT diagram for
crystallization in an undercooled melt and
conventional vitriﬁcation path. (b) Gibbs free
enthalpy curve for crystal, liquid (stable and
metastable), and glass. Paths 1 and 2 corre-
spond to conventional and solid-state vitriﬁ-
cation paths, respectively. (Taken from [11].)
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at a temperature above Tg only led to crystalline–crystalline polymorphic
transformation [7].
Recently, mechanical milling has also been used to produce solid dispersions
and co-amorphous systems [11, 24–29]. However, studies have shown that
milling produces less physically stable solid dispersions compared to those
prepared by other methods such as spray-drying and melt-quenching [30–32].
Some researchers have attributed this low physical stability to the heterogeneous
relaxation of the milled solid dispersions, as indicated by the lower value of the
relaxation distribution in comparison to the same systems prepared through
spray-drying or melt-quenching [31]. It is also possible that a high proportion of
nuclei are present in solid dispersions prepared by milling, which are available to
undergo recrystallization on storage. Recently, the formation of co-amorphous
materials by milling has been reported. These are complexes of poorly water-
soluble drugs in a solid state with other small molecular entities, mainly via
intermolecular interaction such as salt formation and hydrogen bonding [29] or
interparticle hydrogen bonding [33]. The complexed solids are amorphous in
nature. However, the co-amorphous materials produced by milling have been
reported to have enhanced physical stability and dissolution rate in comparison
to the amorphous APIs alone [26–29]. This has been attributed to the inter-
molecular interactions between the two drug species at certain stoichiometric
ratios, which constrain the molecular mobility of amorphous APIs [26–29].
15.2.2
Thermal Processing Techniques
The basic principles of pharmaceutical thermal processing techniques are
partially or completely based on liquefying either the API alone or the API
with excipients via heating. Thermal processing techniques are mainly used for
controlling or improving the release and the subsequent bioavailability of an API.
In many formulations processed by thermal techniques, the disorder states were
introduced into the API and the polymeric excipients during the cooling process.
The conversion of the crystalline state to a more disordered state, whether
completely amorphous or semicrystalline, can facilitate better control of the drug
release by altering the properties of the excipients in the formulations. A wide
range of thermal processing techniques have been developed or adopted from
other industries to pharmaceutical use over the past few decades. Techniques
such as melt-mixing, spray-congealing, sintering, melt-granulation, and HME
have developed and evolved rapidly for large-scale pharmaceutical produc-
tion [34]. New emerging thermal processing techniques such as dry powder
coating, injection molding, melt-electrospinning, KinetiSol® dispersing, and
melt-based 3D printing have been explored for their potential use for scaled-up
pharmaceutical manufacturing [34, 35].
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15.2.2.1 Simple Melt-Fusion Method
Melt-fusion is the simplest form of thermal processing. It directly liqueﬁes theAPI
and/or excipient, followed by the cooling of mixture into a solid form. If a carrier
excipient is involved,mixing during themolten stage is often facilitated by stirring.
The common carrier materials are usually lipids and low molecular weight (MW)
biopolymers such as fatty acids, triglycerides and self-emulsifying lipids, and low-
MW synthetic polymers, such as PEG, GMO, and poloxamers. These materialsQ2
are mostly crystalline or semicrystalline in nature and have relatively low melting
points.The choice of the carrier material plays an important role in controlling or
enhancing the dissolution of the API.Themolten lipids or polymers can act as the
solvent to dissolve the API at temperatures below the melting point of the pure
crystalline API. The advantage of using such carrier materials is that they often
can facilitate the amorphization of the drug via dissolving the drug in the carrier
material during the molten stage.
After cooling, the crystalline state of the excipient material may also be
disrupted by the incorporation of the API. In the case of triglycerides, the lipids
often solidify as their metastable polymorphs and slowly transform into the stable
polymorph on aging [36–38]. This often leads to physical stability concerns
regarding the formulation [36–38]. For enhancing the dissolution of poorly
soluble APIs, surface-active and self-emulsifying polymers such as Gelucire
and poloxamer are often used as carrier materials. Although in some cases the
poorly water-soluble APIs are not completely converted into the amorphous
state, improvements in the dissolution of the APIs are often still evident [38, 39].
This has been attributed to a number of possible factors including the disorder
introduced during the melt cooling (such as the formation of microﬁne crystals
after recrystallization of the drug in the carrier material and partial amorphous
conversion) as well as improved solubilization and wetting by the presence of
surface-active polymers and lipids [38, 39].
The cooling rate of the melt is one of the most important processing parameters
that can aﬀect the degree of disorder. In the case of forming solid dispersions of
API in a meltable carrier material, a faster cooling rate has been associated with
a lower level of drug recrystallization on aging, rapid reaching of supersaturation
state in the dissolutionmedia after dissolution, and enhanced bioavailability of the
formulated drug [40, 41].Melt-quenching is also one of the commonly usedmeth-
ods for converting a crystalline drug to its amorphous state. The melting method
can be applied only to compounds that are thermally stable upon melting [42,
43]. For example, piroxicam starts to degrade upon melting, and thus the use of
melting methods may not be suitable for this compound [43]. In some cases, it
was reported that even the time and temperature allowed for complete melting
could aﬀect the physical properties of the generated amorphous system [32, 44].
For example, Van den Brande et al. reported a signiﬁcant degradation of loviride
processed using slow cooling [44], but obtained a stable amorphous form by using
quench-cooling.
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15.2.2.2 Spray-Chilling/Congealing
Spray-chilling is a thermal-based atomization method for producing spherical
microparticles containing lipid/polymer excipients and API. The basic principle
of spray-chilling is illustrated in Figure 15.3. Droplets of the molten excipients
containing either molten API or suspended undissolved API are formed by
the atomizers and solidify in the collector [45]. The additional advantage of
spray-chilled formulations in comparison to formulations prepared by the
melt-fusion method is their small particle size, which leads to a high surface
area to volume ratio. This large surface area, at least partially, contributed
to the observed improved dissolution of spray-chilled Gelucire–piroxicam
microspheres despite that the API was still largely in its crystalline state [39].
During the spray-chilling process, the lipid/polymer excipients are melted and
cooled. The cooling process leads to the solidiﬁcation and recrystallization of the
processed materials. This often causes increased disorder of the carrier lipids
(recrystallizing to a metastable polymorph) and the API [36–38]. Similar to the
melt-fusion method, this can be attributed to the melting and recrystallization
process of the formulations.
15.2.2.3 Melt-Granulation
Melt-granulation is a process that involves agglomeration of theAPIwithmeltable
binders via direct heating or frictional heating during high-shear mixing. The
binder material can be premelted and sprayed/dripped into the granulator to
form granules, or premixed with the API and then melted during the granulation
process [46]. The most popular industrial-scale melt-granulation can be achieved
by using ﬂuid-bed melt granulators and high-shear mixers [46]. The granules can
be formed through either an immersion-dominated or a coalescence-dominated
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Figure 15.3 (a) Basic operational principle
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Qi et al. [39]. Reproduced with permission
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Figure 15.4 Possible mechanisms of granule formation via melt-granulation.
mechanism, as illustrated in Figure 15.4. The mechanism of the formation of
granules is highly dependent on the amount of molten binder added and the
granulation method used [46].
During themelt-granulation process, the processing temperature is often below
the melting point of the API. Thus disorder is mainly introduced into the car-
rier/binder materials, which experience melting and cooling.The commonly used
binder materials for melt-granulation are similar to those used for spray-chilling.
These are meltable materials with relatively low melting temperatures (between
50 and 80 ∘C), such as Compritol 888 ATO, Gelucire, and low-MW PEG. A num-
ber of studies have reported the combined use of HME with melt-granulation in
order to incorporate polymeric binders with high glass transition temperatures,
such as hydroxypropyl methylcellulose (HPMC) and ethylcellulose (EC) into theQ3
granules. These polymeric additives have shown good capabilities for modulating
the release and disintegration rates of tablets formed by the granules produced by
melt-granulation [47, 48].
15.2.2.4 Thermal Sintering/Curing
Thermal sintering/curing is a less dynamic method in comparison to other ther-
mal processing techniques. It is an additive curing process for preformed pellets,
granules, and compressed tablets under elevated temperature [49, 50]. The pro-
cess can be applied to matrices containing meltable excipients (such as lipids and
semicrystalline polymers) or polymers that can be softened during curing [49, 50].
Sintering/curing is often used to modify, in most cases prolong, the drug release
behavior of the formulation. It has been reported that the sintering process can
cause redistribution of excipients that are thermally responsive [40, 49].This redis-
tribution ofmaterial is believed to be achieved bymelting (formeltable excipients)
or through increasing themolecularmobility of the excipients in the formulations.
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The added advantages of this melting/fusion of excipients in the formulation are
reduced porosity (as seen in Figure 15.5) and the subsequent increase in surface
hydrophobicity of the formulation attributed to the coating [51]. This decreased
porosity and increased surface hydrophobicity can reduce the wettability of the
formulation and further contribute to the decrease in the drug release rate [51].
For meltable excipients, the thermal sintering/curing process leads to the recrys-
tallization of the excipient after the curing process is completed. Although scarcely
reported in the literature, it is reasonable to predict that lipid-based excipients will
go through metastable to stable polymorphic transformation on aging, and the
degree of crystallinity of a semicrystallized polymer may be reduced after the sin-
tering process. For polymeric excipientswith higher glass transition temperatures,
the thermal curing processmay introduce an increased degree of cross-linking and
structural relaxation is expected after the curing process [49, 51].
15.2.2.5 Dry Powder Coating
Dry powder coating is a process using thermal sintering/curing that converts
a dry powder deposited on a surface to a ﬁlm coating on the surface. This is a
solvent-free coating method requiring suﬃcient adherence of the dry powder to
the surface at the ﬁrst stage of the process. There are a number of dry powder
coating techniques based on the adsorption mechanism of the powder layer
including liquid-assisted powder deposition, thermal adhesion deposition,
and electrostatic deposition [52, 53]. In order to achieve the desired product
attributes, novel excipients are often required for these speciﬁc manufacturing
processes. The success of a dry powder coating process strongly depends on the
physical properties of the coating and substrate materials and the interaction
between the interfaces formed during the process [52, 53]. Hydrophilic semicrys-
talline polymers with a low melting point (e.g., polyethylene glycol 3350) are
the most frequently used excipients for dry powder coatings. However, other
amphiphilic and hydrophobic excipients, such as Pluronic 127 and cetylstearyl
alcohol, have also been used. When the processing temperature is above the glass
transition temperature of a coating material, the formed ﬁlm is more “liquid-like”
and more susceptible to plastic deformation. As the relationship between the
melt viscosity and temperature follows the Arrhenius equation, reduced viscosity
can be achieved by using high processing and curing temperatures, which leads to
the formation of a higher quality ﬁlm. A suﬃcient reduction of the viscosity of the
coating material can result in the formation of capillary forces, which facilitate in
the adherence of the coating to the solid surface. Under high temperature condi-
tions, surface energy diﬀerentials can act as the driving force for the spreading of
the semimolten polymer and enhance the coating eﬃciency [52, 53] (Figure 15.6).Q4
15.2.2.6 Hot-Melt Extrusion (HME) and Injection Molding
The ﬁrst use of HME was reported in 1930s for plastic manufacturing as well as in
the food industry. It was invented at the end of the eighteenth century by Joseph
Brama for the production of lead pipes. This technique was then extensively used
in the plastics industry in the middle of the nineteenth century for providing
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Figure 15.5 SEM images of Eudragit E PO powder ﬁlms after thermally sintered/cured at
80 ∘C for (a) 1 h, (b) 2 h, (c) 4 h, (d) 8 h, (e) 12 h, and (f ) 24 h. (Adapted from Cerea et al. [51].
Reproduced with permission of Elsevier.)
polymeric insulation of wires [54]. More recently, HME has been adopted for
producing solid-dispersion-based systems [54, 55]. HME is a single continuous
process that involves mixing, melting, homogenizing, and shaping [56]. The
ability to process the materials in this way is an obvious requirement associated
with HME, and the number of suitable excipients is currently limited. However,
the method has the ﬂexibility of being able to use multiple additives such as
plasticizers as well as stabilization and solubility/absorption enhancers (such as
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Figure 15.6 Illustration of the essential steps of dry powder coating. (Adapted from Sauer
et al. [52]. Reproduced with permission of Elsevier.)
surfactants) to optimize the processing behavior and physical performance of the
ﬁnished dispersions. Amorphous solid dispersions prepared by HME have shown
to be able to enhance the dissolution and absorption of poorly soluble drugs, such
as indomethacin, itraconazole, felodipine, celecoxib, and ketoprofen (100–106).Q5
Other potential applications include targeted and controlled-release dosage
forms, multiple unit dosage forms, ﬂoating dosage forms, implants, transdermal
and transmucosal delivery systems, as well as the formation of nanocomposites
for prolonged release [54–56].
The HME process can be divided into three typical zones: the feeding zone,
the melting or compression zone, and the metering zone. Each of the zones has
a diﬀerent geometrical screw design that dictates the advance of the process for
melting and mixing materials [55]. Because of the elevated operating tempera-
ture (at least 30–60 ∘C above the Tg of the material in order to suﬃciently soften
the processed materials) and the high level of shear generated by the rotation
of the mixing barrels, high levels of disorder can be created during HME. Mix-
tures of polymers, API, and additives are passed through the feeding system and
processed within a closed barrel to allow solubilizing of API in the polymeric
matrix. At the end of barrel, high pressure applied within themetering zone forces
the molten mass to be extruded through an oriﬁce to produce a product of high
density and uniformity [54–56]. Subsequently, the molten material is transported
to the downstream equipment for ﬁnal dosage form manipulation such as melt-
pelletization, milling, and tableting.
As with other solid dispersion preparation methods, despite the high number
of reported successful case studies in the academic literature, the number of
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hot-melt-extruded amorphous solid dispersion products is still very limited.
This can be partially attributed to the poor understanding of the material
behavior during HME processing and the post processes. Studies on the devel-
opment of inline analysis of the dispersions during extrusion processing have
been tried, showing promising potential for adoption in industrial production
[57, 58]. These analytical tools can not only detect in-process degradation
and uneven mixing of the drug and excipients but also be used to study the
interaction between the drug and polymers in the molten state and under
the shearing of the extrusion process. Advanced local and bulk characterization
techniques, such as solid-state NMR (SSNMR), atomic force microscopy (AFM),
photothermal-microspectroscopy (PT-MS), and thermal transition mapping
(TTM), have been used to study hot-melt-extruded solid dispersions on a
submicrometer scale in order to gain a better understanding of the disorder
in extruded solid dispersions as a result of processing, such as higher level of
surface drug recrystallization in comparison to the core of HME extrudates
[59–61].
Injection molding is a manufacturing process of shaping thermoplastic or ther-
moset materials in a closed mold via the application of high temperature and
pressure [62]. It is often used in conjunction with HME. It has the advantage
over conventional HME in allowing a single-step shape formation of formulations
that require precise and/or complex geometries, such as transdermal micronee-
dles or intravaginal rings [63, 64]. Recently, there has been growing interest in
using injection molding as a single-step manufacturing process to produce tablet-
and capsule-shaped formulations for oral controlled release [65]. The injection
molding process introduces additional stress to the hot-melt-extruded samples to
allow the material to remelt, which is then forced into the mold under high pres-
sure.However, inmost cases, without additional quenching, the cooling process of
injectionmolding is slower in comparison toHME alone.This is because themold
is a large piece of solid metal that has to be preheated to an elevated temperature.
Therefore, once the material is injected into the mold, the cooling of the mold to
ambient temperate takes much longer than the cooling of the strands of exudates.
It is well known that for thermal-melting-based methods, the disorder created
during the process is highly dependent on the cooling rate. Therefore injection-
molded solid dispersions are expected to be diﬀerent from HME dispersions in
terms of the degree of disorder. However, this has not been extensively studied
and requires more work for a better understanding and control of the injection
molding process.
15.2.2.7 Other Emerging Thermal Processing Techniques
A range of new thermal processing techniques have been recently developed for
manufacturing pharmaceutical formulations. Melt-electrospinning and KinetiSol
dispersing (KSD) are two good examples that have shown promising potential in
the preparation of solid-dispersion-based formulations. Melt-electrospinning is a
modiﬁcation of the conventional electrospinning technique [35]. This processing
technique can producemicro-ﬁbrous structures from polymermelts.The distinct
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diﬀerence between melt-electrospinning and solution-electrospinning (which
will be discussed in a later section in this chapter) is that the electriﬁed molten
polymer jet lacks the random dynamic chaotic motion observed in solution-
electrospinning. This means that the collection of melt-electrospun ﬁbers can
be highly controlled and aligned into predesigned patterns [35]. This has been
attributed to the higher viscosity and lack of electrical conductivity of the molten
polymer. However, the disadvantage of melt-electrospinning is that the diameters
of the produced ﬁbers are within the 5–40 μm range instead of in the nanometer
range [35]. Melt-electrospinning has been used to produce amorphous solid
dispersions [66], which provided faster dissolution of a poorly soluble model drug
in comparison to hot-melt-extruded dispersions. This was attributed to the high
surface area of the ﬁbrous formulation. However, the long-term physical stability
of the amorphous drug in this form has not been widely studied. As a result of
the high surface area, surface instability is expected for this type of formulation
on aging (Figure 15.7).
Q6
Q7
Another good example of an emerging new thermal-based pharmaceutical pro-
cess is the patented KSD technology. This process uses the frictional heat gen-
erated by the shear of sample powder against the paddles rotating at high speed
within a cylindrical chamber to melt the API and the excipients to form solid dis-
persions [67]. In contrast to other thermal processing techniques for producing
solid dispersions, the KSD method of elevating the temperature, which leads to
the melting of the material, occurs within seconds. This gives this technique the
unique advantage of being able to process many thermos-labile APIs that cannot
be processed using other thermal methods. The ultrafast temperature elevation
accompanied by high shear has also been reported to be able to achieve a higher
level of mixing between the drug and polymer in comparison to other thermal
processes such as HME [68]. For example, hot-melt-extruded itraconazole and
HPMC show phase separation of drug-rich and polymer-rich domains, whereas
only a single miscible phase can be detected by diﬀerential scanning calorimetry
(DSC) in the KSD solid dispersions [68]. Therefore, KSD technology seems to be
a good method for intentionally incorporating a high level of disorder into the
processed formulations.
15.2.3
Solvent-Evaporation-Based Processing Techniques
Solvent-evaporation-based methods are important processing techniques for
both raw materials, such as crystallization of the raw drug, and formulation
manufacturing in the pharmaceutical industry. As crystallization is not within
the scope of this chapter, we will solely focus on the processing that can poten-
tially induce the formation of the disordered state during the manufacture of
formulations. The widely used solvent-evaporation-based processing techniques
in pharmaceutical formulation production include spray-drying, freeze-drying,
ﬁlm casting, and ﬁlm coating. There are new, innovative techniques still at
bench-scale development, such as spray-freeze-drying, solution electrospinning,
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Figure 15.7 Melt-electrospinning setup and the micro and nanoﬁbers produced by melt
electrospinning. (Adapted from Brown et al. [35]. Reproduced with permission of Wiley.)
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and spin coating, which have shown great potential for the preparation of highly
sophisticated formulations.
15.2.3.1 Spray-Drying
Spray-drying is a unit operation for transforming liquid solutions or suspensions
into solid products by rapidly atomizing the solutions/suspensions and drying
them with a hot gas. Modern spray-drying technology can process thermo-liable
materials, such as proteins and peptides through careful manipulation of the pro-
cessing parameters and selection of excipients [69]. It is a well-established tech-
nology for the formation of solid microparticles, with applications in the delivery
of poorly soluble drugs, proteins, vaccines, and inhalation therapies [69, 70]. The
nature of solidifying the formulation via rapid, complete solvent removal leads
to an inherent high potential for forming disordered states in the product either
intentionally or unintentionally.
A spray-drying process can be divided into the atomization and drying steps.
The atomization step produces droplets of the starting solution.The performance
of the atomizer directly impacts on the size of the dried particles. There are four
main types of industrially used atomizers: rotary atomizers, pressure nozzles, two-
ﬂuid nozzles, and ultrasonic atomizers [71].Thedroplet size can also be inﬂuenced
by the feed concentration and solution viscosity of the starting solution.This stage
is less likely to contribute to the generation of disorder to the system in comparison
to the drying step.
The drying stage is a complex transformation process from droplet to dry
particles involving both heat and mass transport in a timescale of milliseconds
[72]. During this step, there are rapid and signiﬁcant changes at the surfaces of
the droplets in terms of distribution and movement of the components [70, 72].
For solutions containing polymers andmacromolecules, during drying signiﬁcant
surface adsorption of the molecules leads to surface enrichment and saturation
followed by shell formation and complete solidiﬁcation of the hollow particles
[70]. However, if the diﬀusion of the solutes is relatively fast, they remain evenly
distributed in the entire droplet. This leads to low surface enrichment and the
formation of solid particles instead [70].
Regardless of the geometry of the particles, the formation of disorder during
the drying stage is governed by the intrinsic properties of the solutes. For small
molecules, whether the solidiﬁcation process leads to crystallization or the forma-
tion of the amorphous form is highly dependent on the glass transition temper-
ature in relation to the drying outlet temperature and the crystallization kinetics
of the material. For large molecules with slower diﬀusion coeﬃcients in solution,
the disorder can be concentrated and immobilized at the shell of the particles after
drying.Therefore, spray-drying has been used to prepare solid dispersions of small
molecular weight drugs with polymeric carriers to intentionally form amorphous
state of the drug in order to achieve faster dissolution [69, 70]. The intimate mix-
ing following dissolution in a common solvent with the polymer and rapid drying
can have the equivalent eﬀect of fast quenching and “freeze” the drug molecules
in a molecular dispersion with the polymeric carrier [69, 72]. For example, the
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second-generation non-nucleoside reverse transcriptase inhibitor, etravirine, for
treating resistant HIV, was unable to provide eﬃcient bioavailability if formulated
into nanocrystals or solid dispersions via HME or ﬁlm casting, but has proven
to be successful when formulated as a spray-dried amorphous dispersion with
HPMC [6].
15.2.3.2 Freeze-Drying
Freeze-drying, also known as lyophilization, is a well-established process that is
traditionally used for used for stabilizing labile substances or processing phar-
maceuticals of biological origin such as proteins, serum, vaccines, peptide drugs,
and liposomes, often administered parenterally [73]. Recently, the application of
freeze-drying has been signiﬁcantly expanded to includemanufacturing orally dis-
integrating tablets (ODTs) and fast dissolving tablets and ﬁlms (FDTs), wafers
for buccal delivery and wound healing, inhalable powders, and 3D scaﬀolds [74].
Many of the novel applications of freeze-drying are related to its ability to produce
low-density and highly porous material.
The freeze-drying process can be divided into three stages: freezing, primary
drying, and secondary drying. In the freezing step, the solvent (typically water) is
separated from the solute to form ice crystals. This leads to the solute molecules
concentrating as separate micro-islands, and this process is termed freeze con-
centration [73].This formation of phase-separated, concentrated domains and ice
crystals is the ﬁrst step, which may initiate the formation of disordered phases.
Therefore, the widespread opinion is that the primary drying stage should be con-
ducted at temperatures below Tg to ensure the maintenance of the stability of
macromolecules in particular [75]. However, some studies have demonstrated that
freeze-drying at temperatures well above Tg without the need for vitriﬁcation can
still preserve the activity of proteins as a result of the slow unfolding kinetics of
proteins in relation to the timescale of the freeze-drying process [75].
The primary drying process involves the sublimation of ice under high vacuum
with elevated shelf-temperature in order to supply the heat required for ice subli-
mation. The sublimated ice is then condensed on a cooled plate/coils (< –50 ∘C)
in the condenser [73]. The secondary drying phase removes any residual mois-
ture content at a further increased temperature (i.e., 25–60 ∘C). Applying a low
pressure at elevated temperature further dries any “unfrozen” water in the “freeze
concentrate.” For labile materials such as proteins, the drying temperatures and
their duration are critical for retaining protein activity and post-process stabil-
ity. These two drying steps are time consuming and can give the system time to
further develop any disordered phase formed during the freezing step. However,
the literature does not show any discussion on the eﬀect of drying conditions
on the stability of the freeze-dried, low-MW compounds.
In order to expand the applications of the freeze-drying process to produce
microparticles, in recent years, freeze-drying has been used in conjunction with
spray-drying. This combined technology is called spray-freeze-drying. Spray-
freeze-drying has been used to prepare solid dispersions for the delivery of poorly
soluble APIs [76]. A few studies have reported the ability of using freeze-drying
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to stabilize amorphous drugs in a solid dispersion and the superior physical
stability and dissolution performance of freeze-dried solid dispersions compared
to other solvent-evaporation-based methods [76, 77].The underlying mechanism
of this enhancement is still poorly understood. This may be attributed to the low
operating temperatures in comparison to other solvent-basedmethods. However,
the powder obtained from this method often have poor ﬂowability as a result of
its low density, which can potentially aﬀect downstream processing for tableting
or capsule-ﬁlling.
15.2.3.3 Film Coating and Casting
Film coating is one of the most commonly used pharmaceutical processes
for coating solid dosage forms such as tablets and pellets for the purpose of
taste-masking as well as controlled and targeted drug release [78, 79]. There are
two main types of ﬁlm coating: aqueous ﬁlm coating and organic solvent ﬁlm
coating. The main components in a coating solution are the coating polymer
and plasticizers. The coating liquid is sprayed on to the solid tablets/pellets in a
coating pan with continuous (hot) air ﬂow for drying. The process parameters,
such as spray rate, atomizing air pressure, inlet air temperature, and the rotation
speed of the pan, can signiﬁcantly aﬀect the quality of the ﬁlm formed [78,
79]. If the heterogeneity of the coating ﬁlm is considered to be a degree of
disorder, alteration of process parameters and optimization of solution properties
such as viscosity, solid content, and interfacial tension at the solid tablet/pellet
surface will facilitate the minimization of the disorder created during the
process.
Conventional ﬁlm casting is a more static method compared to ﬁlm coating,
and is considerably diﬀerent from spray-drying with regard to both ﬁlm for-
mation and the rate of solvent removal. The drying process of the ﬁlm casting
method can be accomplished with or without elevated temperatures and vacuum.
However, the rate of solvent removal in the ﬁlm casting method is much slower
than in the spray-drying and ﬁlm coating processes. In the cases of using ﬁlm
casting to prepare solid dispersions, the physical structure of the ﬁnished solid
dispersion can be signiﬁcantly inﬂuenced by the solvent removal rate. Janssens
and coworkers compared the solid dispersions of itraconazole prepared by ﬁlm
casting and spray-drying methods [4, 6].The experimental solubility of the modelQ8
drug in the casted ﬁlms was much lower than that measured for the spray-dried
dispersions. Although these results were ascribed to the eﬀect of the manu-
facturing methodology used on the physical structure of the resulting solid
dispersion, the mechanism underlying the observed deviation in solubility is
still not well understood [4, 6]. It is possible that, during the casting process,
the local drug concentration increases with continuous removal of solvents
from the ﬁlm. This may create domains with high drug concentration, which
exceeds the saturation solubility of drug in the polymer. These domains may then
act as nuclei for drug recrystallization. If the crystallization kinetics of the drug
is faster than the solvent removal, a crystalline drug would be expected in the
ﬁnished ﬁlm.
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15.2.3.4 Emerging Solvent-Evaporation-Based Processing Technologies
Electrospinning and spin coating are two emerging solvent-based processing
technologies that have been recently adopted for pharmaceutical formulation
preparation [80–82]. Electrospinning and electrospraying are two electro-
hydrodynamic techniques that have wide biomedical applications and have
just recently been introduced to the pharmaceutical community for the
preparation of amorphous solid dispersions [80, 81]. Electrospinning is a
process in which a strong electrical potential is applied to a liquid (a solu-
tion or molten mixture of the drug and a polymer). At a critical voltage, a
charged liquid jet of the sample solution is ejected from the tip of the liquid
droplet and travels toward a collector connected to a grounded electrode
[82–84]. On the journey to the collector, the solvent evaporates and nano-
or microﬁbers can be formed and collected on the collector, which can be
of diﬀerent geometries. By altering the viscosity of the liquid solution and
the processing parameters, electrospinning can be transformed into electro-
spraying, in which well-separated micro- and nanoparticles can be obtained
[80–84]. In comparison to the amorphous solid dispersions formed using other
solvent-evaporation-based methods, electrospun ﬁbers can oﬀer even better
improvements in the dissolution enhancement of amorphous solid dispersion
containing poorly soluble drugs as a result of their unique process-related
features such as high surface area to volume ratio and highly porous inter-
connected network structure with tunable pore size (the pores refer to the
spaces created between the ﬁbers) [80, 81]. However, these characteristics
may compromise the physical stability of the formulation. The high surface
area exposed to the external environment can accelerate phase separation
and crystallization of drug from the ﬁbers. However, the physical instability
and crystallization behavior in these nano- and microﬁbers are still poorly
understood.
Spin coating is a rapid solvent-evaporation-based process that prepares thin
and ultrathin ﬁlms with controllable thickness (normally micrometer to nanome-
ter thickness) on a substrate, as illustrated in Figure 15.8. It has been widely used
in microfabrication in the semiconductor industry [85]. Unlike the traditional
pharmaceutical ﬁlm casting and ﬁlm coating, the rate of solvent evaporation
in spin coating is much higher because of the high spinning speed (normally
1000–10 000 rpm). This rapid solvent evaporation and solidiﬁcation process
can reduce the risk of clustering and phase separation of the drug in the ﬁlms
by shortening the time the system is not in the solid state (before the solvent
has completely evaporated). With the advantages of high reproducibility, fast
preparation, and precise control of the manufacturing process, spin coating has
been used to prepare amorphous solid dispersions for experiments designed
to provide a fundamental understanding of the physical stability of amorphous
solid dispersions [82, 86–88]. For example, Ng et al. used spin coating toQ9
prepare solid dispersions containing model drugs including celecoxib, felodipine,
fenoﬁbrate, and carbamazepine and polymers with diﬀerent hygroscopicities
[82]. It has been reported that the key factors that aﬀected the physical stability
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Figure 15.8 Procedure of using spin coating to prepare a thin ﬁlm on a substrate.
of the solid dispersions under stressed humidity were the intrinsic physical
stability of drugs alone and the hygroscopicity of polymers. In another study
from the same group, drug migration from the bulk toward the surface of the
spin-coated amorphous solid dispersion thin ﬁlms of felodipine–PVP K29/32
was discovered during aging under stressed humidity [83, 87]. It has been
reported that the ﬁlm thickness can have signiﬁcant eﬀects on the crystal
growth and hydrophobicities of the spin-coated crystalline polymeric ﬁlms
[82]. Therefore, it will be interesting to further investigate the relationship
between the ﬁlm thickness and the degrees of instability/crystallization on
aging.
15.3
Conclusion
In a broad sense, disorder can be classiﬁed as any change of the molecular
arrangement from its original form. If focusing on crystalline APIs, the degree of
disorder increases with the change from crystal to crystal defects and eventually
to the amorphous state. If focusing on semicrystalline polymers, the degree of
disorder can be a decrease in the amount of crystalline domains in the polymer.
In this chapter, commonly used and emerging pharmaceutical processing tech-
nologies were discussed with respect to their ability to create disordered states
in the ﬁnished products either intentionally or unintentionally. Milling-based
methods gradually build up the degree of disorder into the system, and signiﬁcant
accumulation of the disorder can eventually convert a crystalline material to
an amorphous one. This is very diﬀerent from the melting and solvent-based
methods. Thermal melting and solvent-based methods start by introducing
complete disorder into the systems either via melting the API with the excipients
or dissolving them in a common solvent. The degree of disorder recovers during
the second stage of the process, which is either cooling or drying. The conversion
of disorder back to the low-energy crystalline state is often associated with
physical instability of the formulations. A better understanding of the generation
of disorders and their impact on the clinical outcome of the formulations requires
a ﬁrm knowledge of the process and the characteristics of the material during
and after processing.
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